Belize
Tuberculosis profile
| High HIV burden |
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.02 (0.02–0.02) 5.9 (5.9–6)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.9 (0.54–1.4)
Prevalence  (includes HIV+TB) 0.13 (0.055–0.23) 39 (17–70)
Incidence  (includes HIV+TB) 0.12 (0.11–0.13) 37 (34–40)
Incidence (HIV+TB only) 0.029 (0.026–0.031) 8.6 (7.8–9.4)
Case detection, all forms (%) 99 (91–110)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.1) 100 (29–100)
MDR-TB cases among notified pulmonary
TB cases
3 (2–4) 3 (1–3)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 75   0
Pulmonary, clinically diagnosed 43   0
Extrapulmonary 3   0
       
Total new and relapse 121    
Previously treated, excluding relapses 3    
Total cases notified 124    
Among 121 new and relapse cases:
4 (3%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 6 (8%) 8 (267%) 14
Laboratory-confirmed RR-/MDR-TB cases     3
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 121 (98)
HIV-positive TB patients 25 (21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 21 (84)
HIV-positive TB patients on antiretroviral therapy (ART) 25 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 55
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 53
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-26 Data: www.who.int/tb/data